Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases, has announced the pricing of its offering of US$275 million aggregate principal amount of 4.00% convertible senior notes due 2029 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933. The offering size was increased from the previously announced offering size of US$200 million aggregate principal amount of notes. The issuance and sale of the notes are scheduled to settle on April 17, 2023, subject to customary closing conditions. Mirum also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional US$41.25 million principal amount of notes.
Latham & Watkins LLP represents the initial purchasers in the offering with a capital markets team led by New York/Los Angeles partner Greg Rodgers, Orange County/Bay Area partner Shayne Kennedy, and Los Angeles partner Arash Aminian Baghai, with associates Ryan Gold, Eric Hanzich, Andrew Bentz, and Allison (AJ) Blair. Advice was also provided on intellectual property matters by Bay Area/San Diego partner Christopher Hazuka, with associates Robert Yeh and Kristina Funahashi; on tax matters by Bay Area partner Grace Lee, with associate Emmanuel Kassim; and on regulatory matters by Washington, D.C. partner Elizabeth Richards.